Clinical trials: copd or chronic obstructive
Chronic Obstructive Pulmonary Disease
12-week Efficacy of Indacaterol
This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.
- Trial name
- NCT01072448
- Testing
- Indacaterol 75 μg
- Where
- 62 sites in United States
- Volunteers
- 323 people
- Sponsor
- Novartis
Asthma, COPD
Breathing Parameter Measurements for Lung Deposition Simulation
This study aims to simulate the deposition of aerosol drugs within the airways of asthma and COPD patients based on realistic breathing patterns measured at different pulmonology centers.
- Trial name
- CHOICE (NCT05445349)
- Testing
- Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy
- Where
- 3 sites in Hungary
- Volunteers
- 163 people
- Sponsor
- Medisol Development Kft.
Chronic Obstructive Pulmonary Disease
Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS
This study is to evaluate if add-on treatment with inhaled NVA237 (50 µg) once daily (o.d.) via single-dose dry-powder inhaler (SDDPI) further improves lung function and health status and is well tolerated compared to placebo in…
- Trial name
- GLOW8 (NCT01757015)
- Testing
- NVA237
- Sponsor
- Novartis Pharmaceuticals
COPD
RUSSE / Russian Spiriva® Safety & Efficacy Study
At the moment, there is hardly any structured safety and efficacy data collection on Tiotropium in Russia. Therefore, the objective of this observational study is to collect and evaluate data on bronchodilator efficacy and safety…
- Trial name
- NCT00613574
- Testing
- tiotropium-bromide
- Where
- 33 sites in Russia
- Volunteers
- 407 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD).
Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069
Study to investigate safety, tolerability and effect of multiple dosing with AZD 4721 and/or with AZD 5069
- Trial name
- NCT01962935
- Testing
- AZD4721, AZD5069
- Where
- United Kingdom
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Homogeneous Emphysema
Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study
The purpose of the study is to evaluate the efficacy and safety of the 20 mL BLVR System in patients with homogeneous emphysema.
- Trial name
- NCT00630227
- Testing
- Biologic Lung Volume Reduction
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- Aeris Therapeutics
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
- Trial name
- NCT00064402
- Testing
- arformoterol tartrate inhalation solution, Salmeterol
- Where
- 65 sites in United States
- Volunteers
- 741 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Bronchitis
A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis
Identifying the role of antibiotics in the treatment of subjects with a microbiologically documented acute exacerbation of chronic bronchitis (AECB) is the purpose of this clinical trial.
- Trial name
- NCT00255983
- Testing
- Faropenem medoxomil
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Replidyne
Asthma, Respiratory Candidiasis
The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases
This study tests the effects of an experimental drug PC945 in people with asthma or other chronic respiratory diseases whose lungs are infected by Aspergillus fungi and Candida yeasts.
- Conditions
- Asthma, Respiratory Candidiasis, Respiratory Aspergillosis, COPD
- Trial name
- NCT03745196
- Testing
- PC945
- Where
- 4 sites in United Kingdom
- Volunteers
- 13 people
- Sponsor
- Pulmocide Ltd
Chronic Obstructive Pulmonary Disease COPD
Realize the Current Situation of COPD Patients in China
This is a multi-centre, prospective, observational study to realize the current situation of COPD patients in China. About 5000 COPD patients will be enrolled from 50 participating sites around China and followed up for one year.
- Trial name
- REAL (NCT03131362)
- Where
- China
- Volunteers
- 5,020 people
- Sponsor
- AstraZeneca
Alpha 1-Antitrypsin Deficiency
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
The purpose of this clinical study (ChAMP - Comparability pharmacokinetics of Alpha-1 Modified Process) is to compare the pharmacokinetic, safety and tolerability of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1…
- Trial name
- ChAMP (NCT00295061)
- Testing
- Alpha-1 MP, alpha-1 proteinase inhibitor (human)
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Grifols Therapeutics LLC
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Pulmonary Disease, Chronic Obstructive
Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)
To explore the mechanisms of dyspnea relief during exercise in patients with COPD following treatment with tiotropium bromide (Spiriva)
- Trial name
- NCT00274027
- Testing
- tiotropium bromide
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
GVHD, Chronic
Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)
This is a phase 2, open-label, multicenter trial to evaluate the efficacy and safety of BN101 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least First Line of systemic therapy.
- Trial name
- NCT04930562
- Testing
- BN101
- Where
- 7 sites in China
- Volunteers
- 30 people
- Sponsor
- BioNova Pharmaceuticals (Shanghai) LTD.
Pulmonary Disease, Chronic Obstructive
Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy
The decrease in physical activity due to increasing dyspnoea that over time leads to a steadily worsening condition and increasing restriction of physical functioning is a key problem for COPD patients and affects even the early…
- Trial name
- NCT02173769
- Testing
- Spiriva® Respimat®, Striverdi® Respimat®
- Where
- 701 sites in Germany
- Volunteers
- 1,845 people
- Sponsor
- Boehringer Ingelheim
COPD (Chronic Obstructive Pulmonary Disease)
Study That Will Evaluate the Brazilian Population With COPD.
Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic…
- Trial name
- SCOPe (NCT06780046)
- Where
- 10 sites in Brazil
- Volunteers
- 693 people
- Sponsor
- AstraZeneca
Asthma
Study of Daclizumab in Patients With Chronic, Persistent Asthma
The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to…
- Trial name
- NCT00028288
- Testing
- Daclizumab
- Where
- 18 sites in United States
- Volunteers
- 120 people
- Sponsor
- Facet Biotech
Asthma
The Extended Salford Lung Study ("Ex-SLS") Data Access Project
The Salford Lung Study (SLS) subjects represent a group of COPD and asthma patients whose disease is extremely well-characterised over a short time period.
- Trial name
- NCT03152669
- Where
- United Kingdom
- Volunteers
- 1,183 people
- Sponsor
- GlaxoSmithKline
Pulmonary Emphysema in Alpha-1 PI Deficiency
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)
This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed…
- Trial name
- SPARTA (NCT01983241)
- Testing
- Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP
- Where
- 52 sites in United States, Argentina and 15 more
- Volunteers
- 345 people
- Sponsor
- Grifols Therapeutics LLC
Pulmonary Disease, Chronic Obstructive
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times…
- Trial name
- NCT00239473
- Testing
- 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
- Where
- 38 sites in Germany, Italy and 2 more
- Volunteers
- 429 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.